Workforce

How the United States' Massive Failure to Close the Digital Divide Got Exposed By Coronavirus

Three out of four Americans without reliable high-speed internet access live in urban areas. Most haven’t connected because they can’t afford it.

Workforce

Coronavirus Roundup: TSA Goals Shaped by Pandemic; Senators Question Immigration Court Reopenings 

There's a lot to keep track of. Here’s today’s list of news updates and stories you may have missed.

Management

Officials Detail Preparations for 'Inevitable' Coronavirus Surge This Fall

Dr. Anthony Fauci and others say their agencies are taking "financial risks" to pursue potential treatments and a vaccine, but will not compromise science.

Management

Inside the Trump Administration’s Decision to Leave the World Health Organization

Despite Trump’s declared exit from the WHO, officials continued working toward reforms and to prevent withdrawal. Then, they were told they must justify any cooperation with the WHO on the grounds of national security and public health safety.

Management

Facing a COVID-19 Resurgence and Unable to Act

Coronavirus cases are going up, but lockdowns seem less realistic than ever.

Oversight

How — and When — Can the Coronavirus Vaccine Become a Reality?

It is likely we’ll eventually have a coronavirus vaccine — but perhaps not as quickly as some expect. From development, to clinical trials and distribution, ProPublica reporter Caroline Chen explains the tremendous challenges that lie ahead.

Oversight

House Democrat Asks Inspectors General to Review Agencies' Reopening Plans

"Your continued oversight is critical to protect the health and safety of our government’s most valuable resource: its federal workforce," Connolly wrote. 

Oversight

For Experts Who Study Coronaviruses, a Grim Vindication

They warned that the next great pandemic would be a coronavirus, but research funding went to studying other threats.

Management

Analysis: Could Pressure for COVID-19 Drugs Lead the FDA to Lower Its Standards?

The FDA has sped up its approval process for coronavirus treatments, creating a new division to expedite the regulatory process. But is safety being sidelined for speed?